It is a peptide that works on tissue repair, blood vessel formation, and inflammation control
On analyzing obesity classification based on BMI, the researchers found that the chances of GLP-1 use were 1.73 times higher among class 1 obesity patients (BMI, 30.0-34.9), 2.19 times higher among class 2 obesity patients (BMI, 35.0-39.9), and 2.69 times higher among patients with class 3 obesity (BMI 40) than among overweight patients (BMI, 25.0-29.9)
Each professional brings a unique perspective and expertise, contributing to a comprehensive, patient-centred care model in which interdisciplinary collaboration is essential to address the diverse clinical, metabolic, and psychosocial challenges posed by obesity [16, 145]
Yes, but that depends on your situation
Given the coupling between copper and energy status (e.g copper is a cofactor at Complex IV of the ETC) and how intensely metabolically active neurons are, it seems like short-term IP GHK-cu in the brain is acting analogously to the copper ionophore elesclomol in Tregs
For semaglutide, that meant 1.7 mg or 2.4 mg.[1] All participants also received guidance on nutrition and physical activity throughout the trial